Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-11-05EMA Authorised: Pegasys (peginterferon alfa-2a) — pharmaand GmbH
EMA authorised Pegasys (peginterferon alfa-2a) for chronic hepatitis C, chronic hepatitis B, polycythemia vera, and essential thrombocythemi…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. …
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) [Phase 2]
Extension-phase update for bomedemstat (IMG-7289/MK-3543) in myeloproliferative neoplasms. The Phase 2 extension study in essential thromboc…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of GLB-001 in Patients With Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial evaluating GLB-001 in patients with myeloid malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance [Phase 3]
Phase 3 trial comparing ropeginterferon alfa-2b (P1101) to anagrelide in essential thrombocythemia patients with hydroxyurea resistance or i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET [Phase 2]
A single-arm Phase 2 study evaluating P1101 in adults with essential thrombocythemia; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia [Phase 2]
Phase 2 clinical trial (Ruxo-BEAT) evaluating ruxolitinib in high-risk polycythemia vera or high-risk essential thrombocythemia; the study i…
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 [Phase 2]
Phase 2 clinical trial update of IMG-7289, an LSD1 inhibitor, in essential thrombocythemia. The study is active but not recruiting, with res…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History [NA]
This clinical trial update describes a study assessing the prevalence of germline gene mutations in patients with myeloproliferative neoplas…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm [Phase 1]
Phase 1 clinical trial update for a CALR-mutant peptide vaccine in myeloproliferative neoplasms; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]
Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 clinical trial update from Bristol-Myers Squibb evaluating SAR302503 in polycythemia vera or essential thrombocythemia; the study st…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
This clinical trial investigates how extracellular vesicle–driven senescence contributes to myeloproliferative neoplasms, including essentia…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. [NA]
A completed pilot clinical trial evaluating a diagnostic score to differentiate myeloproliferative neoplasms, including essential thrombocyt…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients [Phase 3]
Phase 3 trial evaluating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia; the study is currently active but …
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Efficacy and Safety of Peginterferon in ET and PV. [NA]
This document reports a currently recruiting clinical trial evaluating the efficacy and safety of peginterferon in essential thrombocythemia…
-
CLINICAL_TRIALS research · 2024-12-05Clinical Trial Update: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
A recruiting clinical trial is evaluating ruxolitinib in patients with myelofibrosis, including primary myelofibrosis and myelofibrosis seco…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients [Phase 3]
An extension study of P1101 is planned after completion of Phase 2 in polycythemia vera or Phase 3 in essential thrombocythemia; the trial i…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: Aquagenic Pruritus in Myeloproliferative Neoplasms
A completed clinical trial investigating aquagenic pruritus in patients with myeloproliferative neoplasms.
-
FDA approval · 2024-09-23FDA Approved: HYDROXYUREA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for Hydroxyurea, confirming an updated approval for the generic produ…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) [Phase 2]
Phase 2 LIMBER-213 evaluated the safety, tolerability, and efficacy of Itacitinib immediate-release tablets in adults with primary or second…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Myeloproliferative Neoplasms (MPNs) Patient Registry
An update on the Myeloproliferative Neoplasms (MPNs) Patient Registry sponsored by University Health Network in Toronto, currently recruitin…
-
FDA label_change · 2024-08-16FDA Approved: ANAGRELIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for Anagrelide by Torrent Pharmaceuticals Limited, updating the labeling for the drug.
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Myeloproliferative Neoplastic Diseases Observatory From Brest
A Brest-based clinical trial observatory update for myeloproliferative neoplasms, enrolling patients with polycythemia vera, essential throm…
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia [Phase 2]
This is a Phase 2 clinical trial comparing pegylated interferon alfa-2b to interferon alfa in adults with essential thrombocythemia; the stu…